|
| related topics |
| {product, candidate, development} |
| {stock, price, share} |
| {stock, price, operating} |
| {product, liability, claim} |
| {competitive, industry, competition} |
| {personnel, key, retain} |
| {provision, law, control} |
| {control, financial, internal} |
| {property, intellectual, protect} |
| {acquisition, growth, future} |
| {product, market, service} |
| {cost, contract, operation} |
|
|
RISKS RELATED TO OUR BUSINESS
WE DO NOT HAVE THE RESOURCES TO BECOME A FULL SCALE BIOTECHNOLOGY COMPANY AND WE MAY NOT BE ABLE TO ATTRACT A NECESSARY BUYER/LICENSEE/PARTNER.
WE HAVE NOT YET SUCCESSFULLY COMMERCIALIZED NATURLOSE.
OUR SOLE DRUG CANDIDATE IS STILL IN THE EARLY STAGES OF DEVELOPMENT AND REMAINS SUBJECT TO CLINICAL TESTING AND REGULATORY APPROVAL. THIS PROCESS IS HIGHLY UNCERTAIN AND WE MAY NEVER BE ABLE TO OBTAIN MARKETING APPROVAL FOR OUR DRUG CANDIDATE.
IF CLINICAL TRIALS OF NATURLOSE ARE PROLONGED, DELAYED OR SUSPENDED, IT MAY TAKE SIGNIFICANTLY LONGER AND COST SUBSTANTIALLY MORE TO OBTAIN MARKETING APPROVAL FOR OUR DRUG CANDIDATE AND ACHIEVE PROFITABILITY, IF AT ALL.
WE CURRENTLY RELY ON THIRD PARTIES TO CONDUCT OUR TRIAL, AND THOSE THIRD PARTIES MAY NOT PERFORM SATISFACTORILY.
EVEN IF OUR CLINICAL TRIALS ARE SUCCESSFUL, WE MAY NOT HAVE A COMMERCIALLY VIABLE DRUG OR PRODUCT.
IF PHYSICIANS AND PATIENTS DO NOT ACCEPT NATURLOSE, WE MAY NOT BE ABLE TO GENERATE SIGNIFICANT REVENUES FROM PRODUCT SALES.
BIOTECHNOLOGY BUSINESS HAS A SUBSTANTIAL RISK OF PRODUCT LIABILITY CLAIMS. THE DEFENSE OF ANY PRODUCT LIABILITY CLAIM BROUGHT AGAINST US WILL DIVERT MANAGEMENT TIME AND REQUIRE SIGNIFICANT EXPENSE.
OUR PATENT PROTECTION MAY NOT BE SUFFICIENT TO PROTECT US.
WE HAVE SUSTAINED LOSSES IN THE PAST AND WE MAY SUSTAIN LOSSES IN THE FUTURE.
WE MAY NOT BE ABLE TO OBTAIN ADDITIONAL FINANCING IF NEEDED.
WE MAY NOT BE SUCCESSFUL IN OUR NEWLY-FORMED HEALTH SCIENCES CONSULTING BUSINESS.
WE MAY NOT BE ABLE TO RETAIN OUR KEY EXECUTIVES AND PERSONNEL.
WE FACE INTENSE COMPETITION BY COMPETITORS.
RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK
THE PRICE OF SPHERIX S COMMON STOCK HAS BEEN HIGHLY VOLATILE DUE TO SEVERAL FACTORS WHICH WILL CONTINUE TO EFFECT THE PRICE OF OUR STOCK.
OUR COMMON STOCK WILL BE DELISTED FROM NASDAQ GLOBAL MARKET SYSTEM IF WE FAIL TO COMPLY WITH CONTINUED LISTING STANDARDS.
DIVIDENDS ON OUR COMMON STOCK ARE NOT LIKELY.
BECAUSE OF THE RIGHTS AGREEMENT AND ANTI-TAKEOVER PROVISIONS IN OUR CERTIFICATE OF INCORPORATION AND BYLAWS, A THIRD PARTY MAY BE DISCOURAGED FROM MAKING A TAKEOVER OFFER WHICH COULD BE BENEFICIAL TO OUR STOCKHOLDERS.
INSIDERS OWN A SIGNIFICANT PORTION OF OUR COMMON STOCK, WHICH COULD LIMIT OUR STOCKHOLDERS ABILITY TO INFLUENCE THE OUTCOME OF KEY TRANSACTIONS
Full 10-K form ▸
|
|
| related documents |
| 1017491--3/12/2008--NEXMED_INC |
| 1010086--3/13/2008--SIGA_TECHNOLOGIES_INC |
| 873303--3/16/2007--AVI_BIOPHARMA_INC |
| 873303--3/16/2006--AVI_BIOPHARMA_INC |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 873303--3/10/2009--AVI_BIOPHARMA_INC |
| 908259--3/16/2010--OXIGENE_INC |
| 1013238--3/31/2006--ARADIGM_CORP |
| 352747--3/16/2007--UNIGENE_LABORATORIES_INC |
| 908259--3/14/2008--OXIGENE_INC |
| 874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA |
| 708717--10/14/2008--ALFACELL_CORP |
| 908259--3/14/2006--OXIGENE_INC |
| 1114872--3/29/2006--MILLENNIUM_CELL_INC |
| 907562--3/3/2006--DYAX_CORP |
| 873303--3/16/2010--AVI_BIOPHARMA_INC |
| 908259--3/14/2007--OXIGENE_INC |
| 1038133--3/31/2006--HESKA_CORP |
| 1038133--3/30/2007--HESKA_CORP |
| 1203866--2/29/2008--PHARMION_CORP |
| 817785--4/4/2007--IMMUNE_RESPONSE_CORP |
| 1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC |
| 352747--3/16/2006--UNIGENE_LABORATORIES_INC |
| 887247--4/2/2007--CELLEGY_PHARMACEUTICALS_INC |
| 708717--10/15/2007--ALFACELL_CORP |
| 1110803--3/6/2006--ILLUMINA_INC |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 1133416--3/15/2006--PRO_PHARMACEUTICALS_INC |
| 907562--3/13/2007--DYAX_CORP |
| 897075--3/14/2007--REPROS_THERAPEUTICS_INC. |
|